Previous 10 | Next 10 |
This article was highlighted for PRO+ subscribers, Seeking Alpha's service for professional investors. Find out how you can get the best content on Seeking Alpha here . The CAR-T space got a bit ahead of itself over the last 3-4 years. Now that the buzz has subsided after two big buyouts ...
Introduction Cellectis ( CLLS ) is a clinical-stage biotechnology company developing off-the-shelf, allogeneic CAR T (“UCART”) therapies with its leadership in gene editing through its flagship technology, TALEN, which has been successfully used in the clinic to solve key ...
The word "biotech" often gets used interchangeably with "biopharma," but that's not quite correct. Biopharmaceuticals are just one part of the broader sector, which also includes agricultural biotech, industrial biotech, and several other subsectors. It's an important distinction for investors t...
AMELI-01 Clinical Trial Uses New UCART123 Construct With Optimized Production Process & New IND Number First Patient Dosed at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage bi...
Healthcare companies are gathering in San Francisco this week for the annual JP Morgan Healthcare Conference, a high-profile event that's historically been a great venue for announcing mergers and acquisitions (M&A) and licensing agreements. So far, there haven't been any big M&A deals,...
SAN CARLOS, Calif. and NEW YORK, Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biopharmaceutical...
Cellectis and World Experts Review New Avenue of Allogeneic CAR T-cells, Optimization and Promises in Oncology Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth:ALCLS; Nasdaq:CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogen...
For all of the wondrous potential of immunotherapies, there have been some notable obstacles in the early goings. Engineering immune cells to attack cancerous tumors can lead to solid results shortly after administering a dose, but for many patients the effects wear off once rapidly mutating tum...
BALLI-01 Clinical Trial Commenced at MD Anderson Cancer Center Regulatory News: Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic C...
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...